Skip to main content

Invasive Fungal Infection

3
Pipeline Programs
5
Companies
4
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
2 programs
1
Posaconazole IV 6 mg/kgPhase 2
Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCTN/A
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
1
Posaconazole IV 6 mg/kgPhase 21 trial
Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCTN/A1 trial
Active Trials
NCT00460330Unknown120Est. Dec 2008
NCT04665037Recruiting40Est. Dec 2026
Biosergen
BiosergenSweden - Solna
1 program
1
BSG005Phase 1/21 trial
Active Trials
NCT06678113Recruiting15Est. Apr 2026
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCTN/A
Astellas
AstellasChina - Shenyang
1 program
Isavuconazonium sulfateN/A1 trial
Active Trials
NCT03066011Completed2,015Est. Apr 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Sharp TherapeuticsPosaconazole IV 6 mg/kg
BiosergenBSG005
AstellasIsavuconazonium sulfate
Sharp TherapeuticsEvaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCT

Clinical Trials (4)

Total enrollment: 2,190 patients across 4 trials

NCT04665037Sharp TherapeuticsPosaconazole IV 6 mg/kg

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

Start: Feb 2022Est. completion: Dec 202640 patients
Phase 2Recruiting
NCT06678113BiosergenBSG005

Study to Assess the Safety and Efficacy of Intravenous BSG005 in Patients With Invasive Fungal Infection

Start: Jul 2024Est. completion: Apr 202615 patients
Phase 1/2Recruiting
NCT03066011AstellasIsavuconazonium sulfate

Registry of Patients Treated With Systemic Mold-Active Triazoles

Start: Mar 2017Est. completion: Apr 20202,015 patients
N/ACompleted
NCT00460330Sharp TherapeuticsEvaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCT

Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCT

Start: Apr 2007Est. completion: Dec 2008120 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 2,190 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.